Showing 2951-2960 of 3223 results for "".
- Midwest Vision Partners Announces Partnership with Specialty Eye Institutehttps://modernod.com/news/midwest-vision-partners-announces-partnership-with-specialty-eye-institute/2477268/Midwest Vision Partners (MVP), an eye care management services organization backed by private equity firm Alpine Investors, has announced its partnership with Specialty Eye Institute (SEI). Terms
- ReFocus Eye Health Acquires Soll Eyehttps://modernod.com/news/refocus-eye-health-acquires-soll-eye/2477266/ReFocus Eye Health, a collaborative healthcare organization, announced that it has acquired Soll Eye. The acquisition, effective immediately, brings all four Soll Eye locations across Pennsylvania and <
- ForwardVue Pharma CEO: “Short Path to the Clinic” for Retinal Disease Treatmenthttps://modernod.com/news/forwardvue-pharma-ceo-short-path-to-the-clinic-for-retinal-disease-treatment/2477263/In an interview with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco, ForwardVue Pharmaceuticals CEO Alan Franklin, MD, PhD, who is an ophthalmologist, said the company’s lead molecule aims to treat retinal neovascular disease.
- Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for DR and DME from Apexian Pharmaceuticalshttps://modernod.com/news/ocuphire-pharma-announces-in-license-of-phase-2-oral-small-molecule-drug-candidate-for-dr-and-dme-from-apexian-pharmaceuticals/2477254/Ocuphire Pharma announced that it has entered into an agreement with Apexian Pharmaceuticals, granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first
- The Vision Council Notes That U.S.-China Trade Agreement Will Result in Tariff Reductions on Certain Optical Productshttps://modernod.com/news/the-vision-council-notes-that-u-s-china-trade-agreement-will-result-in-tariff-reductions-on-certain-optical-products/2477239/The trade deal between the US and China that requires structural reforms to China’s economic and trade regimes will also lead to a modification of a portion of the existing Section 301 China tariffs, according to The Vision Council, as
- IrisVision and Samsung Announce Partnership to Roll Out Vision Correction Software Platformhttps://modernod.com/news/irisvision-and-samsung-announce-partnership-to-roll-out-vision-correction-software-platform/2477229/Samsung Electronics and IrisVision announced a strategic partnership to roll out IrisVision’s technology worldwide. IrisVision’s vision correction software platform utilizes the power of Samsung’s industry leading Galaxy smartphones and XR devices and mobile AI platform to enable people
- Improved Reimbursement for Endoscopic Cyclophotocoagulation (ECP) when Combined with Cataract Surgeryhttps://modernod.com/news/improved-reimbursement-for-endoscopic-cyclophotocoagulation-ecp-when-combined-with-cataract-surgery/2477219/Beaver-Visitec International (BVI) expressed support for two new CPT codes and improved reimbursement for ECP when combined with cataract surgery. Up to 1 in 5 patients [1] undergoing cataract extraction suffers from glaucoma, and ECP remains an important option for ophtha
- Eyevensys Closes $30M Series B Financinghttps://modernod.com/news/eyevensys-closes-30m-series-b-financing/2477210/Eyevensys announced that it has completed a $30 million Series B financing. The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic noninfectious uveitis (NIU), including the launch of its Electro Study. This phase 2 trial, to
- IrisVision and Samsung Announce Partnership to Bring Clinically Validated Vision Technologies to Over 200 Million Low Vision Patients Globallyhttps://modernod.com/news/irisvision-and-samsung-announce-partnership-to-bring-clinically-validated-vision-technologies-to-over-200-million-low-vision-patients-globally/2477207/Samsung Electronics and IrisVision announced a strategic partnership to roll out IrisVision’s technology worldwide. IrisVision’s vision correction software platform uses the power of Samsung’s Galaxy smartphones, XR devices, and mobile AI platform to enable people
- New Analysis Expands on Link Between Pharma Payments, Prescribinghttps://modernod.com/news/new-analysis-expands-on-link-between-pharma-payments-prescribing/2477201/Doctors who receive money from drugmakers related to a specific drug prescribe that drug more heavily than doctors without such financial ties, a new ProPublica analysis found. The pattern is consistent for almost all of the most widely pr